Au

Board Addition at Xanadu

Friday, April 9, 2021 - 11:25pm

TORONTO, April 09, 2021 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) wishes to advise the appointment of Tony Pearson as a Non-Executive Director of the Company, effective 3 May 2021.

Key Points: 
  • TORONTO, April 09, 2021 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) wishes to advise the appointment of Tony Pearson as a Non-Executive Director of the Company, effective 3 May 2021.
  • Mr Pearson is an experienced industry executive and company director who has lived and worked in Mongolia, China, Hong Kong, the Philippines and Indonesia.
  • He has a strong understanding of emerging jurisdictions, balanced with the need for western governance practices.
  • Colin Moorhead, Non-Executive Chairman, said Tony will make a strong addition to the Xanadu Board, which is now made up of a majority of Independent Non-Executive Directors.

Genetic Technologies Provides Update on COVID-19 Risk Test Launch

Friday, April 9, 2021 - 4:15pm

Genetic Technologies advises that the Company has completed all validation and data-based analysis for the COVID-19 Risk Test.

Key Points: 
  • Genetic Technologies advises that the Company has completed all validation and data-based analysis for the COVID-19 Risk Test.
  • IBX, our US based distribution partner is currently completing the technical interface with their telehealth partner for the commercial availability of the COVID-19 Risk Test across the United States.
  • GTGs COVID-19 Risk Test may enable the risk assessment of an individual developing a serious disease should they contract the COVID-19 virus.
  • The COVID-19 Risk Test is intended to predict disease severity using a combination of genetic and clinical information.

Immutable X Launches Gas-Free Layer-2 Solution Paving the Way to Mainstream NFT Adoption

Thursday, April 8, 2021 - 2:00pm

Through Immutable X, its layer-two scaling solution, Immutable aims to promote mainstream NFT adoption by offering gas-free minting and trading, self custody alongside seamless UX for developers and consumers.

Key Points: 
  • Through Immutable X, its layer-two scaling solution, Immutable aims to promote mainstream NFT adoption by offering gas-free minting and trading, self custody alongside seamless UX for developers and consumers.
  • Immutable X is also ensuring any NFT activity on the protocol is completely carbon neutral by purchasing carbon credits to offset gas consumed on Ethereum.
  • With todays Immutable X Alpha release, any NFT can now be traded, earned, shared, gamed and collected completely gas-free on Ethereum, said Robbie Ferguson, Immutable Co-Founder.
  • NFTs on Immutable X are carbon neutral: any NFT, marketplace or game built Immutable X is 100% carbon neutral.

Moneta Extends Gold Mineralization at the South West & Windjammer South Deposits at Golden Highway

Thursday, April 8, 2021 - 1:00pm

Significant gold mineralization has been intersected up to 150 m south of and over a strike length of 700 m between the South West and Windjammer South resources.

Key Points: 
  • Significant gold mineralization has been intersected up to 150 m south of and over a strike length of 700 m between the South West and Windjammer South resources.
  • Drilling was focussed on extending the South West mineralization to the south, where it remains open, and connect the Windjammer South and South West resources.
  • MGH20-168 intersected zones of gold mineralization up to 4.00 m @ 3.54 g/t Au including 1.00 m @ 8.54 g/t Au, 12.00 m @ 0.64 g/t Au including 2.98 m @ 1.25 g/t Au, and 11.00 m @ 0.53 g/t Au including 2.00 m @ 1.99 g/t Au and 11.00 m @ 0.47 g/t Au.
  • Drill hole MGH21-174 intersected up to 12.00 m @ 1.57 g/t Au including 1.05 m @ 5.82 g/t Au, 7.60 m @ 2.04 g/t Au including 1.65 m @ 6.36 g/t Au including 0.95 m @ 8.59 g/t Au, 10.00 m @ 1.64 g/t Au including 1.50 m @ 4.20 g/t Au and 1.50 m @3.21 g/t Au and 32.00 m @ 1.63 g/t Au including 1.00 m @ 7.62 g/t Au, 1.12 m @ 6.50 g/t Au and 1.20 m @ 5.56 g/t Au, and 7.00 m @ 1.08 g/t Au including 0.90 m @ 5.19 g/t Au.

Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

Thursday, April 8, 2021 - 1:00pm

Interim clinical data from TACTI-002 was presented at the Society for Immunotherapy of Cancer (SITC) in November 2020.

Key Points: 
  • Interim clinical data from TACTI-002 was presented at the Society for Immunotherapy of Cancer (SITC) in November 2020.
  • FDA Fast Track designation is awarded to help important new therapies reach patients earlier.
  • More information on Fast Track designation is available on the US FDAs website.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy

Wednesday, April 7, 2021 - 1:00pm

The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.

Key Points: 
  • The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immuteps IMP701 antibody which is out-licensed to Novartis AG.
  • In particular, the claims of the patent are directed to compositions comprising LAG525 and spartalizumab, an anti-PD-1 antibody molecule, and related methods of use of the combination in the treatment of cancer.
  • The patent is co-owned by Novartis AG and Immutep S.A.S.
  • IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.)

BlueCat taps industry pioneers for IT community's first annual DDI Day celebration

Tuesday, April 6, 2021 - 1:00pm

TORONTO, April 06, 2021 (GLOBE NEWSWIRE) -- BlueCat, the Adaptive DNSTM company, announced today that it will be hosting the first annual, industry-wide celebration called DDI Day on April 13th.

Key Points: 
  • TORONTO, April 06, 2021 (GLOBE NEWSWIRE) -- BlueCat, the Adaptive DNSTM company, announced today that it will be hosting the first annual, industry-wide celebration called DDI Day on April 13th.
  • DDI Day recognizes the heroic efforts of IT professionals who keep these services working, and consequently, our world moving.
  • DDI Day celebrations will feature:
    A panel discussion by industry pioneers Paul Mockapetris, Ralph Droms, and Russ White.
  • An open invitation for the public to recognize a DDI professional via social networks using the hashtags #DDIHero #DDIDay.

Opthea Company Secretary Resignation

Tuesday, April 6, 2021 - 10:30am

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Key Points: 
  • Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
  • Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities.
  • Opthea strongly recommends that professional investment advice be sought prior to such investments.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law.

Recce Pharmaceuticals Announces Positive Data Against Streptococcus pneumoniae Sinusitis Infection in Animal Model

Thursday, April 1, 2021 - 1:00pm

This bacterium was chosen due to its immediate availability as a recognized sinusitis model.

Key Points: 
  • This bacterium was chosen due to its immediate availability as a recognized sinusitis model.
  • Three groups of mice were treated with varying intravenous doses of R327 (100, 500, 1,000 mg/kg) which showed significant dose-dependent antibacterial effect when compared to early infection control and vehicle control (p
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435 and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Analytica Announces Expansion of PeriCoach® Pelvic Health Solution into China

Wednesday, March 31, 2021 - 12:00pm

Joint venture will also leverage extensive network of over 30,000 clinicians in 100 cities to distribute PeriCoach in China.

Key Points: 
  • Joint venture will also leverage extensive network of over 30,000 clinicians in 100 cities to distribute PeriCoach in China.
  • Analytica partners with Hebei NACOL Bio-Technology Co., Ltd (Nacol) and Shijiazhuang Biosphere Pty Ltd (Biosphere), based in Hebei Province.
  • With CFDA clearance, PeriCoach can become a prescription treatment, initially covering the hospital network in the North China area.
  • Analytica Ltd Chairman, Dr Michael Monsour, comments: Entering the China market with such nimble, experienced operators is a major milestone for Analytica.